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Nanobody Technology: A versatile 
Toolkit for Microscopic imaging, 
Protein–Protein interaction Analysis, 
and Protein Function exploration
Els Beghein and Jan Gettemans*
Nanobody Laboratory, Department of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University,  
Ghent, Belgium
Over the last two decades, nanobodies or single-domain antibodies have found their 
way in research, diagnostics, and therapy. These antigen-binding fragments, derived 
from Camelid heavy chain only antibodies, possess remarkable characteristics that 
favor their use over conventional antibodies or fragments thereof, in selected areas 
of research. In this review, we assess the current status of nanobodies as research 
tools in diverse aspects of fundamental research. We discuss the use of nanobodies 
as detection reagents in fluorescence microscopy and focus on recent advances in 
super-resolution microscopy. Second, application of nanobody technology in investi-
gating protein–protein interactions is reviewed, with emphasis on possible uses in mass 
spectrometry. Finally, we discuss the potential value of nanobodies in studying protein 
function, and we focus on their recently reported application in targeted protein degra-
dation. Throughout the review, we highlight state-of-the-art engineering strategies that 
could expand nanobody versatility and we suggest future applications of the technology 
in the selected areas of fundamental research.
Keywords: nanobody, vHH, single-domain antibody, engineering, super-resolution microscopy, protein–protein 
interactions, targeted protein degradation, fundamental research
iNTRODUCTiON
Since the discovery of heavy chain only antibodies (HcAbs) in 1993 by the Hamers-Casterman’s 
group (1), the use of their antigen binding fragments or nanobodies in research, diagnostics, 
and therapy has evolved at an incredible pace. HcAbs are unique IgGs that are found in sera of 
Camelidae. These antibodies are devoid of the light chain and lack the first constant domain. 
Consequently, the antigen-binding fragment of HcAbs is solely composed of a single variable 
domain, referred to as VHH (variable domain of the heavy chain of HcAbs), single-domain 
antibody or nanobody, which is only ~15 kDa in size. The variable domains of conventional IgGs 
and HcAbs comprise three complementarity-determining regions (CDRs) that constitute the 
paratope of the antibody (Figure 1). As nanobodies lack the variable domain of the light chain, 
they only contain three instead of six CDRs. These CDRs are organized in three loops, separated 
by more conserved framework regions (FRs) and cluster at the N-terminal side of the nanobody. 
In order to provide an adequate antigen-interacting surface of 600–800  Å2, nanobodies have 
longer CDR1 and CDR3 loops than VHs (variable domain of the heavy chain) of conventional 
antibodies, resulting in similar binding affinities. In dromedary nanobodies, these long loops 
FigURe 1 | Crystal structure of a gelsolin nanobody. A nanobody is typically 
composed of three complementarity-determining regions (CDRs), alternated 
with four framework regions (FRs). CDR1 is depicted in yellow, CDR2 in 
magenta, CDR3 in red, and the FRs are depicted in green. Image of PDB ID 
2X1O (5) created with PyMOL.
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are often connected by a disulfide bond that restricts their flex-
ibility and consequently, favors antigen binding. Normally, FR2 
region of VHs contains highly conserved hydrophobic amino 
acids participating in the interaction with the VL (variable 
domain of the light chain). As this region is water-exposed in 
nanobodies, the hydrophobic amino acids are substituted by 
hydrophilic residues, which reduce the likelihood for aggrega-
tion. This explains the high solubility of nanobodies (2–4).
Nanobodies are thus endowed with favorable characteristics 
in terms of size, solubility, and affinity. Furthermore, nanobodies 
can easily be produced recombinantly in bacteria, yeast, plants, 
and mammalian cell lines (3, 4). When expressed in eukaryotic 
cells as intrabodies, nanobodies accurately bind and trace their 
target as they normally do not appear to suffer from the reducing 
intracellular environment. Nanobodies can easily be equipped 
with a customized tag (e.g., fluorescence, affinity, epitope tag, 
etc.) without losing their affinity or stability (6–9). Moreover, 
nanobodies feature a convex paratope and can, therefore, but 
also due to their small size, bind hidden epitopes in small cavities 
(e.g., active site of enzymes) (10, 11). They mainly bind confor-
mational epitopes (7, 10, 12), but nanobodies recognizing linear 
epitopes have also been reported (5, 13, 14). These unique bio-
chemical and biophysical properties of nanobodies purportedly 
render them superior to conventional antibodies or antibody 
fragments, and make them ideally suited for a myriad of biotech-
nological applications.
Despite the aforementioned benefits of the nanobody tech-
nology, still some drawbacks need to be overcome. First of all, 
unmodified nanobodies are not able to traverse the cell mem-
brane. Using nanobodies in research thus requires transfection 
or transduction in cells, or requires the use of transgenic animals. 
However, several research groups are looking into this issue. 
Possible solutions are coupling the nanobodies to a cell-pen-
etrating peptide (penetratin) (15) or exploiting the Escherichia 
coli type III protein-secretion system (T3SS) (16, 17). Second, 
although quite exceptional, nanobodies can lose their functional-
ity when expressed intracellularly (7). A third and perhaps major 
stumbling block, is the fact that nanobody production (animal 
housing, immunization, library construction, and phage pan-
ning) is equivalent to monoclonal antibody production, CRISPS/
Cas9 mouse knockouts, and hence relatively expensive.
In this review, we assess the current status of nanobodies 
as research tools in diverse facets of fundamental research 
(microscopy, protein–protein interactions and protein function). 
Moreover, we focus on the adaptability of nanobodies, or how 
engineering can expand their versatility, and we discuss future 
opportunities given the current know-how. As the use of nano-
bodies in diagnostics and therapy does not fall within the scope 
of this paper, we refer the reader to some excellent recent reviews 
(18, 19).
NANOBODieS USeD AS ReSeARCH TOOL 
iN MiCROSCOPY
Primary Detection Reagents in 
Fluorescence Microscopy
Several studies confirmed the usefulness of nanobodies as 
equivalent detection surrogates for antibodies in immunocyto-
chemistry (Table  1). de Bruin and coworkers generated and 
characterized anti-Vγ9 and anti-Vδ2-T  cell receptor-directed 
nanobodies that could successfully be used as primary detection 
reagents for Vγ9Vδ2-T  cells in immunocytochemistry (20). 
Bound nanobody was detected using a secondary anti-nanobody 
antibody, followed by a tertiary Alexa Fluor 488-conjugated anti-
body (20). To shorten staining procedure, Jullien and colleagues 
mixed their HA-tagged histon H2A-H2B nanobody (chromati-
body) with an anti-HA antibody for primary staining (9). Using 
a tertiary fluorescently labeled antibody, chromatin-specific 
staining was observed in human HCT116 cells and even in organ-
isms evolutionarily distant from mammals (9). Peyrassol and 
colleagues developed His-tagged ChemR23 G-protein-coupled 
receptor (GPCR) nanobodies and tested their binding specificity 
by immunostaining on fixed CHO cells (21). Visualization was 
performed by using a fluorescently labeled anti-His secondary 
antibody, hence avoiding the use of a tertiary antibody (21).
Equipping nanobodies with organic fluorescent dye bypasses 
the use of a secondary and/or tertiary fluorescently labeled anti-
body and thus makes the staining procedure cheaper and less 
elaborate. Braun and colleagues characterized an anti-β-catenin 
TABLe 1 | Overview of the different nanobody-based applications in microscopy.
Application Strategy Specifics Reference
Microscopy Primary detection reagents in fluorescence microscopy Indirect immunocytochemistry (9, 20, 21)
Direct immunocytochemistry (8, 13)
Primary detection reagents in super-resolution microscopy Anti-GFP and anti-RFP nanobodies N-hydroxysuccinimide (NHS) 
ester-labeling
(22–25)
Nanobodies targeting endogenous 
protein
N-hydroxysuccinimide (NHS) 
ester-labeling
(26)
Cysteine-maleimide-labeling (27, 28)
Sortase A-labeling (29)
Furan-labeling (30)
Intracellular nanobodies as microscopic tracers (6–9, 31–33)
Each application corresponds to the different sections in the main text and the strategies match the different paragraphs therein, which are whether or not further specified.
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nanobody, referred to as BC2-VHH, which recognizes a linear 
epitope of only 12 amino acids with low nanomolar affinity (13). 
Coupling this nanobody to the organic dyes Alexa Fluor 488 or 
ATTO 647 by means of N-hydroxysuccinimide ester-labeling (see 
Primary Detection Reagents in Super-Resolution Microscopy) 
endows it with the capability to visualize BC2-tagged fusion pro-
teins directly (13). Accordingly, Maier and colleagues provided 
their vimentin nanobodies with a fluorescent ATTO 488 tag (8). 
Binding specificity was examined in different cell lines (8). Of 
note, the mentioned VB6 vimentin nanobody is not a genuine 
nanobody, but a variable domain derived from a conventional 
antibody.
Primary Detection Reagents in  
Super-Resolution Microscopy
Diffraction of light limits the resolution of conventional fluo-
rescence microscopy to about 200–300  nm in the lateral and 
500–700  nm in the axial direction, leaving many subcellular 
structures too small to be observed in detail. Several variants 
on fluorescence microscopy, such as confocal or multiphoton 
microscopy, only enhance resolution moderately. Ground-
breaking progress was made in the 1990s, when a number of 
super-resolution techniques arose that achieve resolutions far 
beyond the limit of diffraction, for instance, STED (stimulated 
emission depletion), STORM (stochastic optical reconstruction 
microscopy), or PALM (photoactivated localization micros-
copy) (34, 35). Theoretically, the resolution of these techniques 
can reach molecular scale. In practice however, resolution is 
limited by a combination of intrinsic optical properties and 
sample specific factors. An example of the latter is the size of the 
fluorescent labels, which become significant at high resolution 
(35). Using indirect immunochemistry for protein detection, 
the primary and secondary antibody increases the apparent size 
of the visualized structure or introduces a localization bias of 
10–20 nm (22, 36, 37). Reducing the distance between the antigen 
and fluorescent label (linkage error) can be achieved by directly 
coupling an organic dye molecule to a peptide sequence, which 
is genetically fused to the protein of interest (23, 38, 39). For 
instance, coupling proteins to a 15 amino acid acceptor peptide 
tag, allows enzymatic biotinylation and consequent visualization 
of the protein with fluorophore-labeled monomeric streptavidin 
(23). Nevertheless, in some experiments, genetic engineering or 
overexpression is not appropriate (e.g., in case of human samples, 
peptide interfering with protein interactions or due to lack of 
time). In these cases, large linkage error can be tackled by direct 
immunofluorescence, using fluorescently labeled conventional 
antibodies (40).
Recently, the use of labeled nanobodies as nanoscale dete ction 
tools has emerged (Table 1), since nanobodies are significantly 
smaller than antibodies. Several publications describe the use of 
anti-GFP and anti-RFP nanobodies for super-resolution micros-
copy. These nanobodies target genetically encoded fluorescent 
fusion proteins and are equipped with a strong organic dye, usu-
ally coupled to the nanobody by means of N-hydroxysuccinimide 
ester-labeling (see later in this section) (22–24). The first use 
of this technology was reported by Ries and coworkers (22). 
They labeled individual microtubules in fixed Ptk2 cells stably 
expressing tubulin-YFP. The acquired resolution of 26.9 ± 3.7 nm 
is compatible with a microtubule diameter of 25  nm and is 
considerably smaller than what was achieved with indirect 
immunochemistry using conventional antibodies (±45  nm). 
Moreover, these nanobodies showed also to be valuable tools for 
high resolution live imaging and dual-color microscopy (22). 
Accordingly, Chamma and coworkers used GFP nanobodies 
to live-label synaptogenic adhesion protein neurexin-1β and to 
image transsynaptic contacts in neurons in a dual-color setup 
(23). GFP and RFP nanobodies can also be used to study nuclear 
pore complex (NPC) and caveolae ultrastructure in detail. Unlike 
indirect antibody immunochemistry, nanobody staining resulted 
in a far better approximation of the actual dimensions of both 
structures (24, 25).
Using GFP or RFP nanobodies as detection tool has some 
advantages. First, high-affinity GFP and RFP nanobodies are 
commercially available (41), which makes it possible to visualize 
virtually every protein; even those for which no specific targeting 
moiety is available. Moreover, it allows comparable and quantita-
tive labeling between different proteins. This method can also be 
used to image GFP-tagged proteins from GFP-fusion libraries 
in high throughput (22). Nevertheless, experiments sometimes 
require visualization of endogenous protein or overexpression 
of fusion protein is not appropriate (see above). In these cases, 
FigURe 2 | Mechanisms of different nanobody-labeling strategies for super-resolution microscopy. N-hydroxysuccinimide ester-labeling 1 (top) randomly labels 
primary amines 2 in the nanobody. The other techniques mentioned (cysteine-maleimide, Sortase A, and furan technology) site-specifically label introduced tags 
(respectively, cysteine 5, sortag or LPETG 8, and furylalanine 11).
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endogenous target-specific nanobodies can be used. Excluding 
the GFP/RFP-tag for detection practically minimizes linkage 
error to the length of a nanobody, which is 2–4 nm.
In fact, every nanobody compatible with immunostaining 
can be used for super-resolution microscopy. Different labeling 
techniques have been reported. N-hydroxysuccinimide (NHS) 
ester-labeling 1 of primary amines 2 (R-NH2) is the most 
wide spread labeling strategy (Figure 2). NHS ester derivatives 
of various fluorescent probes are commercially available. The 
carbonyl carbon of the NHS ester reacts with primary amines 
in the nanobody, thereby releasing NHS 3 and crosslinking the 
nanobody with the organic dye 4. Accordingly, Mikhaylova and 
coworkers conjugated their anti-β-tubulin nanobodies with Alexa 
Fluor 647 (26). Applying these nanobodies in super-resolution 
microscopy, they succeeded in resolving individual microtu-
bules, both in vitro and in fixed cells. Furthermore, for densely 
packed microtubules with a 25-nm lattice-to-lattice spacing, 
the resolving power of the nanobodies was 2.5-fold and 10-fold 
higher than primary and primary–secondary antibody labelings, 
respectively (26).
NHS ester-labeling can, however, abolish or reduce antigen-
recognition of the nanobody if the paratope contains primary 
amines that become labeled. Equipping the nanobodies with a 
C-terminal oligo-lysine stretch might divert NHS-labeling from 
intrinsic nanobody lysine residues (24). However, modification 
of multiple lysines can create hydrophobic patches that increase 
unspecific binding and thus background staining (27). Several 
research groups, therefore, attempt to develop a generic site-
specific conjugation method. These techniques make it possible 
to control where and how many labels will be added, resulting in 
a homogeneous nanobody population.
Massa and coworkers labeled anti-HER2 nanobody using the 
cysteine-maleimide strategy (28) (Figure 2). They introduced a 
unique place for conjugation by equipping the nanobody with 
a C-terminal cysteine 5, spaced by a rigid 14 amino acid linker 
from the nanobody sequence. This linker presumably prevents 
the added cysteine from interfering with correct folding of the 
dromedary nanobody interloop disulfide bond. When add-
ing a bifunctional maleimide-label 6, the maleimide double 
bond reacts with the cysteine thiol group, generating a stable 
5Beghein and Gettemans Nanobody Technology in Fundamental Research
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carbon-sulfur bond 7. However, this derivatization strategy 
resulted in a severe reduction in production yields and triggered 
extensive dimerization of the nanobodies at the introduced 
C-terminal cysteine, necessitating an additional reduction step. 
In order to safeguard intradomain disulfide bonds, the reducing 
agent needs to be titrated carefully (28). Pleiner and cowork-
ers used the cysteine-maleimide labeling in order to visualize 
individual NPC proteins or nucleoporins (27). They mutated 
one or more solvent-exposed small residues (framework glycine, 
serine, or alanine) to cysteines or introduced an N or C-terminal 
cysteine in GFP nanobody and several nucleoporin nanobodies. 
These cysteines were subsequently crosslinked with maleimide-
Alexa Fluor 647/488. The conjugation reaction was performed 
at 0°C in order to protect the intradomain cysteines. In confocal 
laser scanning microscopy, all nanobodies produced a bright 
punctuate nuclear rim staining against a very low background, 
even when there was only one dye molecule per nanobody. 
Strikingly, cysteine-maleimide-labeled nanobodies performed 
far better than their NHS ester-labeled counterparts in terms of 
specificity. The nucleoporin nanobodies also performed excellent 
in super-resolution microscopy, providing very detailed views of 
individual NPC proteins (27).
Recently, two novel derivatization techniques were reported 
that hold great promise for future nanobody-labeling with 
organic dyes. First, researchers exploited a transpeptidase 
Sortase A (SrtA) derived from Staphylococcus aureus to label an 
anti-HER2 nanobody with the fluorescent dye Cy5 (Figure  2). 
Therefore, nanobodies were provided with a C-terminal SrtA 
recognition motif or sortag (LPETG) 8, and Cy5 was coupled to 
the pentapeptide GGGYK via the side chain ε-amine of the lysine 
residue 9. SrtA catalyzes the formation of a new peptide bond 
between the threonine of the sortag and the glycine of the penta-
peptide, hence generating a stable bond between nanobody and 
fluorescent probe 10. The labeled HER2 nanobody performed 
excellent in fluorescence reflectance imaging of HER2-positive 
tumors in mice (29).
The furan crosslinking technology comprises a second pot-
ential derivatization approach (Figure 2). Albeit not shown for 
nanobodies yet, researches already successfully labeled thy mosin 
β4 peptides with different fluorescent dyes using this technique. 
Briefly, a furylalanine building block 11 was incorporated into 
thymosin β4 peptide. Photooxygenation of the furan moiety 
results in the formation of a 4-oxo-enal moiety 12. Subsequent 
addition of a NH2NH-coupled label, transforms the furan-con-
taining peptides into pyrrolidinone-based fluorescent probes 13 
(30). As super-resolution microscopy techniques can be exploited 
to their full potential by using nanobodies as detection tool, more 
site-specific conjugation methods will undoubtedly emerge in the 
near future.
intracellular Nanobodies As Microscopic 
Tracers
Target visualization can also be achieved by intracellular expres-
sion of fluorescently labeled nanobodies (chromobodies) or 
nanobodies equipped with an epitope tag that allows antibody 
detection (Table 1). These intrabodies typically do not interfere 
with protein function and allow visualization of the endogenous 
target. Overexpression of (fluorescent) fusion protein is thus no 
longer needed, which frequently induces artificial changes in cell 
behavior (8, 9, 31) or results in a false representation of protein 
dynamics (26). Our lab generated a nanobody against survivin, 
a protein that exerts key roles during mitosis (7). The survivin 
nanobody was equipped with a V5-tag, enabeling immunocy-
tochemical detection using an anti-V5 antibody. The nanobody 
accurately tracks its target during different phases of mitosis and 
moreover, it detects different surviving subpopulations that are 
indiscernible for certain commercially antibodies (7). Similarly, 
intracellular expression of EGFP-tagged nuclear transport fac-
tor 2 (NTF2) nanobodies uncovered a new location of NTF2 
at the centrosome (6). Maier and colleagues on the other hand, 
expressed a set of EGFP-labeled vimentin chromobodies in HeLa 
cells and compared their localization pattern to a canonical anti-
vimentin antibody staining (8). As such, they could identify in 
an early screen which nanobodies are genuine vimentin binders 
(8). Accordingly, Van Overbeke and coworkers validated binding 
specificity of endoplasmic reticulum-directed gelsolin nanobod-
ies by immunocytochemistry (32). Colocalization between 
plasma gelsolin and the V5-tagged nanobodies confirmed proper 
nanobody binding (32). Fluorescent nanobodies are also excel-
lent research tools for live imaging in cells and whole organisms. 
The aforementioned vimentin nanobodies were further utilized 
to monitor endogenous vimentin localization and dynamics in 
A549 lung cancer cells. In this cell-based chromobody model, 
it was possible to monitor dynamic changes of vimentin in 
real-time upon RNAi treatment or induction with TGF-β (8). 
Recently, similar high resolution spatiotemporal antigen tracking 
was reported using histon H2A-H2B (9), β-catenin (31), F-actin, 
and PCNA (33) nanobodies.
NANOBODieS USeD AS ReSeARCH TOOL 
TO iDeNTiFY PROTeiN–PROTeiN 
iNTeRACTiONS
gFP-Targeting Nanobodies
Several studies report the use of a GFP-targeting nanobody to 
study protein–protein interactions (Figure 3; Table 2). Herce and 
colleagues presented the fluorescent-three-hybrid (F3H) strategy 
as an alternative to the well-known yeast two-hybrid (Y2H) tech-
nique (42). They coupled GFP nanobody with a delocalization tag 
that redirects GFP-tagged bait protein and eventually mCherry-
tagged prey toward a well-defined subcellular location. (Co-)
localization of bait and prey can be visualized using fluorescence 
microscopy. Moreover, real-time imaging allows monitoring of 
the inhibition kinetics of interactions induced by drugs. The F3H 
approach was validated for delocalization to various subcellular 
compartments (Lac operator DNA sequence, chromocenters, 
nuclear lamina, and centrioles), for different cell types and spe-
cies (baby hamster kidney, mouse myoblast C2C12, and human 
cervical carcinoma HeLa), emphasizing on the flexibility of the 
technique. F3H does not require specialized equipment (42). 
Moreover, this technique overcomes several important drawbacks 
of Y2H associated with the reporter system or the use of yeast as 
FigURe 3 | Overview of different reported approaches to investigate protein–protein interactions using a GFP-targeting nanobody. In the fluorescent-three-hybrid 
(F3H) strategy (top), the GFP nanobody delocalizes GFP-tagged bait toward a defined subcellular location. The nanobody can also be fused with bait protein and as 
such, relocalize bait toward GFP-tagged membrane protein (middle). Finally, the GFP nanobody can be used to deliver upconversion nanoparticles (UCNPs) toward 
GFP-tagged bait (bottom). Binding between GFP-bait and labeled prey is then validated by colocalization, Förster or lanthanide-based resonance energy transfer 
(FRET or LRET, respectively).
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TABLe 2 | Overview of the different nanobody-based applications to identify protein–protein interactions.
Application Strategy Specifics Reference
Identify protein–protein interactions GFP-targeting nanobodies Fluorescent-three-hybrid (42)
Förster resonance energy transfer (44)
Lanthanide-based resonance energy transfer (45)
Nanobodies in mass spectrometry Affinity-purification mass spectrometry (AP-MS) Classical AP-MS (27, 46)
Footprinting (6)
Virotrap (47)
BioID proximity-labeling (48)
Organellar proteomics (7)
Hydrogen/deuterium exchange (49–52)
Each application corresponds to the different sections in the main text and the strategies match the different paragraphs therein, which are whether or not further specified.
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host (42, 43). To circumvent overexpression of fluorescent fusion 
proteins (bait and prey), one can use a nanobody that targets and 
delocalizes endogenous protein toward predetermined organelles. 
Potential interactors colocalize with the target protein, which can 
be visualized by post-fixation labeling (6). This approach does, 
however, not allow studying interaction or disruption kinetics.
Künzl and coworkers studied vacuolar sorting in plants 
using a GFP nanobody sensor (44). Soluble proteins are sorted 
to the vacuole for degradation. Sorting relies on the activity 
of vacuolar sorting receptors (VSRs) that bind proteins by 
means of a luminal binding domain (LBD). However, not much 
was known about the exact locations (endoplasmic reticulum, 
Golgi, trans-Golgi network/early endosome or multivesicular 
late endosomes) at which VSRs bind or release their ligands. In 
order to investigate this, universal and compartment-specific 
VSR sensors were generated and expressed in tobacco meso-
phyll protoplasts. A full-functional VSR sensor consists of a 
LBD (bait)-equipped GFP nanobody and a GFP-tagged mem-
brane marker protein. The latter fluorescently decorates the 
membrane of a specific compartment, depending on the chosen 
marker (e.g., GFP-calnexin for visualization of endoplasmic 
reticulum). A RFP-coupled model ligand (prey), containing a 
vacuolar sorting motif, was used to study compartment-specific 
interactions between LBD (bait) and ligand (prey). Upon 
co expression and binding of the three constructs, the excited-
state energy from GFP (membrane marker) is transferred to 
RFP (ligand), thereby reducing the fluorescence lifetime of 
GFP. This phenomenon, also called Förster resonance energy 
transfer (FRET), can be detected using fluorescence lifetime 
imaging and makes it possible to discern true binding from 
interaction-independent colocalization. FRET ceases at the cel-
lular compartment when LBD (bait) releases its ligand (prey). 
As such, a novel pathway of vacuolar protein sorting in plants 
was postulated (44).
GFP nanobody has also been exploited as targeting moiety 
for upconversion nanoparticles (UCNPs) in lanthanide-based 
resonance energy transfer (LRET) imaging. In simple terms, 
lanthanide-doped UCNPs are able to convert two or more 
near-infrared photons into one UV/Vis photon. In its turn, this 
photon can sensitize a neighboring acceptor fluorophore. The 
UCNPs were functionalized with anti-GFP nanobody to target 
a bait EGFP-fusion protein. On the other hand, prey protein 
was fused to an acceptor fluorophore. Sensitized fluorescence 
upon LRET from the UCNPs can only be detected when bait 
and prey interact (in)directly. As proof-of-concept, the indirect 
interaction between mitochondrial outer membrane (MOM) 
proteins Tom20 and Tom7 was successfully visualized using 
UCNP LRET (45).
In the latter three studies, a high-affinity GFP nanobody was 
used to study protein–protein interactions in living cells, albeit 
combined with different techniques (F3H, FRET, or LRET). The 
nanobody was utilized as delocalization tool, thereby enriching 
bait and eventually prey at defined subcellular locations (F3H, 
FRET) (42, 44), or was used to target a reporter toward bait pro-
tein (LRET) (45). As such, the GFP nanobody emerges as a highly 
adaptable research tool to study protein–protein interactions.
Nanobodies in Mass Spectrometry (MS) 
and Perspectives
Nanobodies are valuable tools for MS applications (Table  2). 
Recently, nanobodies have been used as an alternative for antibod-
ies in classical affinity-purification mass spectrometry (AP-MS) 
to study protein complexes (27, 46). Their small size minimizes 
background binding and reduces the amount of tryptic peptides 
released from the affinity resin during on-bead digestion (53). 
Hypothetically, background binding in AP-MS can be further 
tackled by nanobody footprinting. In brief, by using nanobodies 
that target different epitopes in the same protein, true interaction 
partners may be displaced. This leaves a footprint; hence the 
name nanobody footprinting (6). Proteins that are shared among 
different nanobody-based APs either represent false positives or 
genuine binders that interact with the antigen at an epitope that 
is not recognized by the nanobodies. False positives can, in their 
turn, be significantly eliminated by using an appropriate control 
nanobody (e.g., GFP nanobody) for AP. This finally results in a 
(shorter) list of bona fide interaction partners. Combining this 
strategy with Virotrap, a lysis-free protein interaction analysis 
method, could improve the study of protein complexes, as 
lysis-sensitive protein complexes are preserved. Virotrap implies 
trap ping a bait protein, together with its putative interaction 
partners, inside protective virus-like particles (VLPs) that bud 
from cells. Following antibody-based enrichment and lysis of 
the VLPs, protein complexes can be analyzed by Western blot 
TABLe 3 | Overview of the different nanobody-based applications to explore protein function.
Application Strategy Specifics Reference
Explore protein 
function
Intracellular nanobodies interfering with protein 
function
(21, 31, 63–68, 70)
Customize existing nanobodies by engineering Delocalization (7, 64)
Converting non-invasive to 
invasive nanobodies
(9)
Targeted protein degradation DeGradFP (72)
Protein interference (Protein-i) (73)
Affinity-directed protein missile (74)
Nanobodies in X-ray crystallography (69, 71, 75–77)
Each application corresponds to the different sections in the main text and the strategies match the different paragraphs therein, which are whether or not further specified.
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or MS. Packing of bait in VLPs is achieved by expression of p55 
HIV-1 GAG-bait fusion protein (e.g., expression of GAG-HRAS 
to detect the HRAS–RAF1 interaction) (47). Similarly, nanobody 
could be fused to a GAG protein and capture its target (and 
target interactors) in VLPs, thus avoiding overexpression of bait 
protein. Lysis-sensitive protein interactions can also be detected 
by using the BioID proximity-labeling strategy. This technique 
implies coupling bait to BirA*, a promiscuous biotin ligase that 
covalently attaches a biotin molecule to exposed lysine residues 
in proximate and interacting prey. All biotinylated prey is sub-
sequently collected by means of streptavidin-AP and analyzed 
with MS. Consequently, the technique allows detection of weak 
and transient protein interactions that could be missed when 
using classical AP-MS (48). Combining BioID with nanobody 
footprinting could provide more details on the epitopes of the 
protein interactome.
In contrast to mitochondria and endoplasmic reticulum, 
peroxisomes are endowed with the ability to import oligomeric 
protein complexes (54–59). Combining this unique feature with 
the nanobody-delocalizing strategy opens up new perspectives 
for studying protein complexes using MS. Essentially, nanobod-
ies can be equipped with a SKL peroxisomal targeting sequence 
that shuttles the nanobody and its target to the peroxisomal 
matrix (7). Target interaction partners could subsequently be 
identified using organellar proteomics. This technique implicates 
a subcellular fractionation step of the organelle of interest (e.g., 
peroxisomes), thus eliminating contaminating cytoplasmic 
proteins. Hence, sample complexity is compatible with the sen-
sitivity of current mass spectrometers, allowing identification of 
low-abundance proteins (60). Moreover, as peroxisomal protein 
catalogs are available (61, 62), it is possible to discriminate true 
interaction partners from intrinsic peroxisomal protein. Of 
note, combining nanobody-induced delocalization with orga-
nellar proteomics has not been reported yet, implicating that 
one could encounter unexpected difficulties. The peroxisomal 
import machinery could possibly face difficulties in transporting 
large protein complexes, although successful import of 240 kDa 
tetrameric catalase has already been reported (54). Moreover, 
in order to obtain significant MS data, peroxisomes need to be 
isolated with high purity and adequate yields. Seeing that mam-
malian peroxisomes contribute to only 1–5% of the cell volume, 
this technique will probably require a substantial amount of 
cell material. Nevertheless, strategies to isolate pure and high 
yield peroxisomal fractions for organellar proteomics have been 
published (61).
As will be discussed in the next section, the nanobody-
binding epitope could be used to identify “weak” spots in 
proteins, which offers opportunities for small molecule devel-
opment. Hydrogen/deuterium exchange MS (HDX-MS) allows 
fast epitope characterization with small amounts of sample 
and has already frequently been used to characterize antibody 
epitopes (49–52). In brief, backbone amide hydrogens of the 
target protein are exchanged with deuterium. This process is 
subsequently repeated for the antibody-target protein complex. 
Antibody binding limits the accessibility of certain backbone 
hydrogens for deuterium exchange or alters the exchange 
rates. Consequently, the resulting MS fractionation patterns 
differ and allow delineation of the antibody epitope (49). We 
believe that this strategy could also successfully be exploited 
for nanobody epitope identification, although this has not been 
published yet.
NANOBODieS USeD AS ReSeARCH TOOL 
TO eXPLORe PROTeiN FUNCTiON
intracellular Nanobodies interfering with 
Protein Function
Nanobodies represent a class of high-affinity inhibitors that, 
unlike RNAi, target proteins directly. They can be expressed in 
cells (intrabodies) with the purpose of knocking out (one or 
more) protein function(s), causing measurable effects (Table 3). 
The ultimate goal is to obtain better insight into otherwise poorly 
understood protein functions and signaling pathways. Moreover, 
this may represent a stepping stone toward rational drug 
development. For example, nanobodies were generated against 
β-catenin, a multi-functional protein, which has roles in cell–cell 
adhesion and transcriptional activation of Wnt responsive genes 
(31, 63). Mutations affecting the β-catenin/Wnt signaling path-
way play a role in many diseases, including cancer. Newnham 
and coworkers developed a nanobody that specifically interfered 
with the transcriptional activating activity of β-catenin (63). This 
nanobody can enable further unraveling of the still intricate 
β-catenin/Wnt pathway. Analysis of the nanobody epitope could 
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offer opportunities for development of small molecule inhibitors 
(63). Our lab obtained thoroughly characterized nanobodies 
against actin binding proteins cortactin, fascin, and L-plastin 
(64–67). We demonstrated their effects on actin bundling or 
branched actin polymerization, as well as their functional effects 
on podosome or invadopodia formation and dynamics, both 
specialized actin-rich membrane protrusions involved in (tumor) 
cell migration and invasion. In this way, we could sort out the 
precise contribution of specific protein domains in podosome or 
invadopodium formation and function (64–67). Our group also 
thoroughly characterized nanobodies against the DNA-binding 
domain of p53. We presented a nanobody that interferes with the 
transcriptional abilities of p53, while maintaining the functional 
architecture of p53 and even permitting p53 DNA-binding (68). 
Unlike other research tools, this nanobody allows targeting 
single functions of p53 with high precision (68). Nanobodies can 
also serve as elegant tools for the study and regulation of GPCR 
function. Different sets of nanobodies were developed against 
the model GPCR β2-adrenergic receptor (β2AR) (69–71). These 
nanobodies stabilize specific inactive or active conformations of 
the β2AR and thus are conformationally sensitive. All nanobodies 
recognize intracellular allosteric epitopes and can be expressed 
as intrabodies, without losing their preference for a distinctive 
GPCR conformation (70). Inhibitory nanobodies can, however, 
also be exploited extracellularly. The aforementioned ChemR23 
nanobodies uniquely recognize ChemR23 GPCR and antago-
nize chemerin-induced receptor activation. As chemerin also 
binds other GPCRs, the nanobodies can be used to discrimi-
nate ChemR23-specific signaling from other chemerin-induced 
pathways (21).
Customize existing Nanobodies by 
engineering
Existing (inhibitory and non-inhibitory) nanobodies can be 
engineered to expand their usefulness as a tool for investiga-
ting protein function (Table  3). Equipping nanobodies with 
an appropriate delocalization tag induces relocalization of the 
antigen–nanobody complex toward predetermined organelles 
and consequently, displaces the protein from where it is needed 
(7, 64). This can induce a loss-of-function, rather than a direct 
functional knockout. Correlating these findings with the use of 
untagged inhibitory nanobodies strengthens which protein func-
tions are (not) important in particular pathways. For instance, 
we compared the effects of a fascin nanobody that disrupts 
fascin-mediated F-actin bundling on matrix metalloproteinase 
9 (MMP-9) secretion, with its MOM-tagged counterpart (64). 
The latter nanobody is provided with a MOM delocalization 
tag and thus delocalizes endogenous fascin toward the outer 
mitochondrial membrane. Unlike untagged fascin nanobody, the 
MOM-fascin nanobody significantly reduced MMP-9 secretion, 
emphasizing a role for fascin in MMP-9 secretion independent of 
its actin-bundling activity (64).
Non-invasive intrabodies can also be engineered in such way 
that they can interfere with normal cell biology. As such, Jullien 
and colleagues transformed their H2A-H2B histon chromatibody 
into an invasive tool by coupling the nanobody to an E3 ubiquitin 
ligase (9). Expression of the fusion protein modifies the ubiquitin 
epigenetic landscape and dramatically distorts DNA double-
strand break signaling and repair (9).
Our understanding of protein function has improved con-
siderably by technologies that manipulate protein levels, such 
as RNAi or Morpholino antisense oligonucleotides. However, as 
these methods operate upstream of the protein level, they depend 
on the turnover rate of their target, thus resulting in limited deple-
tion of long-lived proteins. Moreover, they frequently generate 
off-target effects (78, 79). To address these problems, systems 
directly acting on the protein level have been developed (80–82) 
and this is where also nanobodies can play a role.
Different research groups exploit the universal ubiquitin pro-
teasome pathway in combination with high-affinity GFP nano-
body for targeted protein degradation (72–74). To this end, they 
replaced the substrate recognition domain of cullin-RING E3 
ubiquitin ligase (CRL) complexes with GFP nanobody (72, 73), 
or coupled a GFP nanobody to the recognition domain (74) 
(Figure 4). The CRL complexes are composed of a central cullin 
scaffold that interacts with an E2-recruiting RING protein via 
its C-terminal domain, and with a substrate adaptor protein via 
its N-terminus. The substrate adaptor protein mediates substrate 
specificity and recognizes its target directly (e.g., SPOP) or 
indirectly (e.g., SKP1 or Elongin B/C), the latter necessitating an 
additional adaptor protein (e.g., an F-box protein or VHL) for 
target binding. The CRL complexes ubiquitylate proteins and as 
such, mark them for degradation by the proteasome (83). In the 
deGradFP protocol, a GFP nanobody replaces the substrate rec-
ognition domain of an F-box protein, which in its turn recruits 
GFP-tagged proteins to the SKP1-cullin1 E3 ligase machinery 
(72). Conversely, the Protein interference (Protein-i) technique 
implies substituting the substrate recognition domain of adaptor 
SPOP with GFP nanobody. The GFP nanobody-SPOP fusion 
in its turn mediates GFP-fusion protein toward the cullin3 E3 
ligase complex (73). Finally, the affinity-directed protein missile 
(AdPROM) approach fuses GFP nanobody with the C-terminal 
end of the VHL adaptor protein. This fusion protein mediates 
the association of GFP-tagged proteins with the Elongin B/C-
cullin2 E3 complex for degradation. All techniques resulted 
in specific, fast ubiquitination and consequent proteasome-
dependent degradation of GFP-fusion proteins in mammalian 
cells (72–74), Drosophila (72) and Danio rerio embryos (73). 
Compared to traditional RNAi, Protein-i even depleted proteins 
more rapidly and effectively. However, the Protein-i technique 
is currently limited to nuclear proteins, as the SPOP protein 
contains a nuclear localization signal (73). The deGradFP and 
AdPROM technologies can, however, be used for depletion of 
cytoplasmic proteins (72, 74). In summary, all three techniques 
hijack the same conserved pathway for targeted GFP-fusion 
protein degradation, but differ in range of action (nuclear and/or 
cytoplasmic) and GFP nanobody fusion (substitution of or 
fused with the substrate recognition domain). In theory, these 
techniques can be used for targeted degradation of virtually any 
(endogenous) protein, when replacing the GFP nanobody with 
a nanobody of choice.
Tang and coworkers developed a conditional system in which 
the stability of a nanobody depends upon the expression of its 
FigURe 4 | Schematic representation of reported strategies that combine the ubiquitin proteasome pathway with GFP nanobody for targeted degradation of 
GFP-fusion protein. In the deGradFP and Protein interference approach, the substrate recognition domain of the cullin-RING E3 ubiquitin ligase (CRL) complex is 
replaced by a high-affinity GFP nanobody. The affinity-directed protein missile (AdPROM) technique on the other hand, implies fusing the GFP nanobody with the 
substrate recognition domain of the complex.
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target (84). Therefore, they introduced destabilizing mutations 
in the nanobody FR, which could be transferred across different 
nanobodies (e.g., GFP, HIV-1 capsid protein CA, Escherichia coli 
dehydrofolate reductase nanobody, etc.) and even across nano-
bodies from different camelid species. Presence of the cognate 
antigen confers nanobody stability, whereas antigen absence 
results in proteasomal degradation of the nanobody and its asso-
ciated tags. As such, it is possible to endow antigen-expressing 
subsets of cells with particular features. Tang and colleagues 
for instance exclusively labeled ACH-2 HIV-1 positive T-cells 
for flow cytometry (84). Therefore, they utilized destabilized 
chromobodies recognizing the HIV-1 capsid protein CA. Lack 
of CA expression in uninfected cells causes degradation of the 
destabilized chromobodies, consequently resulting in disappear-
ance of fluorescence. Coupling a destabilized nanobody to Cas9 
even allowed genome editing selectively in antigen-expressing 
cells using CRISPR/Cas (84). In theory, this technique can be 
combined with the aforementioned inhibitory nanobodies or 
with the deGradFP/Protein-i/AdPROM methods to interfere with 
protein function or target proteins for proteasomal degradation 
respectively, exclusively in cells expressing specific intracellular 
epitopes.
Nanobodies in X-Ray Crystallography
Nanobodies also feature as a molecular lens in x-ray crystal-
lography and thus can reveal molecular mechanisms or identify 
functionally important regions in a protein (Table  3). For 
instance, the crystal structure of a nanobody in complex with the 
serine protease urokinase-type plasminogen activator revealed 
valuable information on the mechanism by which peptide 
segments may act as strong protease inhibitors. The nanobody 
inserts its CDR3 loop into the active site of the protease in a 
substrate-like manner and becomes slowly cleaved. However, 
a rigid intra-loop interaction network which interconnects 
the putative scissile bond P1–P1′, holds the leaving group in 
place and favors reformation of the peptide bond over cleavage. 
The reaction reaches a cleavage-resynthesis equilibrium, thus 
rendering the nanobody into a strong inhibitor. Conversely, 
mutating specific amino acids in the CDR3 loop converts the 
nanobody to a strong substrate. These findings demonstrate the 
importance of the conformational rigidity of active-site binding 
peptide segments, when exploited as new protease inhibitors 
(75). On the other hand, Rudolph and colleagues reported the 
X-ray crystal structure of five nanobodies in complex with ricin 
toxin’s enzymatic subunit (RTA) (76, 77). The nanobodies all 
showed different ricin-neutralizing potencies (76, 77, 85). They 
identified RTA neutralizing hotspots which may prove useful in 
subunit vaccine development, seeing the low efficiency of cur-
rent vaccination strategies (76, 77). Finally, when bound to their 
target, nanobodies can stabilize specific protein conformation 
and thus serve as chaperones in crystallography. The aforemen-
tioned β2AR nanobodies, binding different conformations of 
the GPCR, showed to be excellent chaperones in X-ray crystal-
lography (69, 71) and NMR structural research (86), revealing 
the full allosteric potential of the β2AR.
CONCLUSiON AND PeRSPeCTiveS
We have provided a brief overview of the various opportuni-
ties nanobodies offer in fundamental research, generally 
subdivided into the categories microscopy, protein–protein 
interactions, and protein function and we focused on how 
state-of-the-art engineering techniques can expand their ver-
satility. Nanobodies feature small, stabe (intracellularly), and 
soluble high-affinity targeting moieties that can easily be pro-
duced. Moreover, it is possible to engineer nanobodies in such 
a way that they display a desired function or set of functions 
(e.g., fluorescence, delocalization, degradation, etc.), without 
interfering with its binding characteristics. Hence, they are 
highly adaptable. These favorable characteristics stimulated 
their use as research tools in diverse aspects of fundamental 
research. Undoubtedly, in future years, new applications will 
continue to surface.
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